Infinium Pharmachem Ltd
Fundamental Score
Infinium Pharmachem Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of INFINIUM across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Robust Profit Growth (26.98%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Consistent Growth Track Record (32.01% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Strong Profit Growth Track Record (60.97% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Balanced Promoter Holding (59.91%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
5 factors identified
Negative Free Cash Flow (₹-25.96 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Limited Institutional Interest (FII+DII: 0.02%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Infinium Pharmachem Ltd
About INFINIUM
Company Details
INFINIUM Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Infinium Pharmachem Ltd (INFINIUM)?
As of 29 Jan 2026, 10:36 am IST, Infinium Pharmachem Ltd (INFINIUM) is currently trading at ₹216.30. The stock has a market capitalization of ₹371.03 (Cr).
Is INFINIUM share price Overvalued or Undervalued?
INFINIUM is currently trading at a P/E ratio of 39.73x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Infinium Pharmachem Ltd share price?
Key factors influencing INFINIUM's price include its quarterly earnings growth (Sales Growth: 1.29%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Infinium Pharmachem Ltd a good stock for long-term investment?
Infinium Pharmachem Ltd shows a 5-year Profit Growth of 60.97% and an ROE of 11.95%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.
How does Infinium Pharmachem Ltd compare with its industry peers?
Infinium Pharmachem Ltd competes with major peers in the Pharmaceuticals. Investors should compare INFINIUM's P/E of 39.73x and ROE of 11.95% against the industry averages to determine its competitive standing.
What is the P/E ratio of INFINIUM and what does it mean?
INFINIUM has a P/E ratio of 39.73x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹40 for every ₹1 of annual earnings.
How is INFINIUM performing according to Bull Run's analysis?
INFINIUM has a Bull Run fundamental score of 50.6/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does INFINIUM belong to?
INFINIUM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Infinium Pharmachem Ltd.
What is Return on Equity (ROE) and why is it important for INFINIUM?
INFINIUM has an ROE of 11.95%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Infinium Pharmachem Ltd generates profits from shareholders' equity.
How is INFINIUM's debt-to-equity ratio and what does it indicate?
INFINIUM has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is INFINIUM's dividend yield and is it a good dividend stock?
INFINIUM offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has INFINIUM grown over the past 5 years?
INFINIUM has achieved 5-year growth rates of: Sales Growth 32.01%, Profit Growth 60.97%, and EPS Growth 6.76%.
What is the promoter holding in INFINIUM and why does it matter?
Promoters hold 59.91% of INFINIUM shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is INFINIUM's market capitalization category?
INFINIUM has a market capitalization of ₹371 crores, placing it in the Small-cap category.
How volatile is INFINIUM stock?
INFINIUM has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for INFINIUM?
INFINIUM has a 52-week high of ₹N/A and low of ₹N/A.
What is INFINIUM's operating profit margin trend?
INFINIUM has a 5-year average Operating Profit Margin (OPM) of 11.96%, indicating the company's operational efficiency.
How is INFINIUM's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 1.29% and YoY Profit Growth of 26.98%.
What is the institutional holding pattern in INFINIUM?
INFINIUM has FII holding of 0.00% and DII holding of 0.02%. Significant institutional holding often suggests professional confidence in the stock.